Skip to main
  1. Stocks
  2. Personalis Inc
  3. Forecast
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 0%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is viewed positively because its NeXT Personal MRD test is gaining real clinical traction, with Q1'26 volume of 7,815, over 1,000 oncologists ordering the test, and multiple Medicare coverage wins that reduce reimbursement risk and support broader adoption. The company also has an attractive biopharma MRD business tracking to about $20M in 2026, plus a valuable services franchise supporting personalized cancer vaccines, where it has performed the upfront sequencing and tumor profiling work for the MRNA/MRK program. Although standalone profitability has been pressured by gross margin compression from 32% in 2024 to 2% in Q1'26, Personalis ended Q1'26 with $233M of cash and now benefits from Tempus’s larger commercial infrastructure, which should accelerate growth and improve scale economics.

Bears say

Personalis is viewed negatively because the stock has already moved very close to the announced $16.25 deal price, leaving little upside and a poor risk/reward profile if the Tempus acquisition closes as expected over the coming months. The bearish view also reflects business-specific uncertainty, including potential Medicare or commercial payer coverage for the MRD test coming in below expectations, plus volatility in biopharma ordering and demand for personalized cancer vaccines from large pharma. Even with a competitive process and limited MRD market share, the deal’s $1.7 billion valuation at about 17x '26 sales and the unusual $46 termination trigger keep execution risk and valuation concerns elevated.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 0% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Personalis Inc (PSNL) Analyst Forecast & Price Prediction

Get the latest Personalis Inc (PSNL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Personalis Inc (PSNL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Personalis Inc (PSNL) Analyst Forecast & Price Prediction

Get the latest Personalis Inc (PSNL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Personalis Inc (PSNL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PSNL stock data and trends